Glenmark Expands Dermatology Portfolio with Launch of Clindamycin Phosphate Foam

Glenmark Pharmaceuticals Inc., USA has announced the launch of Clindamycin Phosphate Foam, 1%, expanding its dermatology portfolio. This generic version of Mylan's Evoclin Foam is indicated for treating acne vulgaris in patients 12 years and older. The product, which received FDA approval in September 2021, joins Glenmark's roster of 175 generic products authorized for U.S. distribution. With a market size of approximately $12 million annually, this launch strengthens Glenmark's position in the topical antibiotic segment. The company continues to focus on expanding its U.S. product pipeline, with 47 applications pending FDA approval.

Sources: Glenmark Pharmaceuticals Press Release, PRNewswire, NSE India